The limited number, efficacy and risk of undesirable effects of presently available painkillers for use in cats with chronic painful conditions call for the development of mechanistically novel therapeutic agents. This study will seek to prove that t-TUCB, an inhibitor of an enzyme (soluble epoxide hydrolase – sEH) involved in inflammation, will produce significant, dose-dependent pain relief in a reversible model of pain due to inflammation in cats. On the basis of studies in rats and the preliminary data, it is expected that t-TUCB will produce dose-dependent reduction in measures of inflammation and pain relief without clinically significant negative effects.
Grants